LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | Barasertib | 10 | uM | LJP5 | 72 | hr | 1235 | 1550 | 4267 | 0.3632 | 0.1348 |
MCF7 | Vemurafenib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4219 | 4267 | 0.9908 | 0.9890 |
MCF7 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4427 | 4267 | 1.0382 | 1.0428 |
MCF7 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4319 | 4267 | 1.0135 | 1.0155 |
MCF7 | Vemurafenib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4134 | 4267 | 0.9698 | 0.9664 |
MCF7 | Vemurafenib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4159 | 4267 | 0.9760 | 0.9736 |
MCF7 | Vemurafenib | 10 | uM | LJP5 | 72 | hr | 1235 | 3486 | 4267 | 0.8179 | 0.7876 |
MCF7 | Enzastaurin | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4036 | 4267 | 0.9475 | 0.9410 |
MCF7 | Enzastaurin | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4134 | 4267 | 0.9704 | 0.9669 |
MCF7 | Enzastaurin | 0.37 | uM | LJP5 | 72 | hr | 1235 | 4352 | 4267 | 1.0209 | 1.0238 |
MCF7 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1235 | 3931 | 4267 | 0.9231 | 0.9119 |
MCF7 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3734 | 4267 | 0.8768 | 0.8583 |
MCF7 | Enzastaurin | 10 | uM | LJP5 | 72 | hr | 1235 | 2312 | 4267 | 0.5424 | 0.4204 |
MCF7 | Palbociclib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3018 | 4056 | 0.7435 | 0.6816 |
MCF7 | Palbociclib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 2425 | 4056 | 0.5974 | 0.4803 |
MCF7 | Palbociclib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 2124 | 4056 | 0.5232 | 0.3697 |
MCF7 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 1794 | 4056 | 0.4423 | 0.2429 |
MCF7 | Palbociclib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1933 | 4056 | 0.4765 | 0.2981 |
MCF7 | Palbociclib | 10 | uM | LJP6 | 72 | hr | 1235 | 1966 | 4056 | 0.4847 | 0.3111 |
MCF7 | PF562271 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 3573 | 4056 | 0.8807 | 0.8566 |
MCF7 | PF562271 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 3336 | 4056 | 0.8228 | 0.7851 |
MCF7 | PF562271 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 2418 | 4056 | 0.5965 | 0.4794 |
MCF7 | PF562271 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 1591 | 4056 | 0.3922 | 0.1581 |
MCF7 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 986 | 4056 | 0.2430 | -0.1235 |
MCF7 | PF562271 | 10 | uM | LJP6 | 72 | hr | 1235 | 725 | 4056 | 0.1788 | -0.2674 |